Savient Pharmaceuticals, Inc. (SVNT) Announces New Drug
Friday, Savient Pharmaceuticals, Inc. announced the launch of their leading drug KRYSTEXXA. KRYSTEXXA has recently been approved by the U.S. Food and Drug Administration for the treatment of chronic gout. The company's product is now the first and only therapy available to address this condition. John H. Johnson, Chief Executive Officer of Savient, stated "Since receiving FDA approval for KRYSTEXXA, we have focused on preparing for a successful U.S. Launch. Our sales force has completed very thorough and extensive training. We are excited to deploy this highly talented and biologics experienced team into their territories. There has never been a…